Hyeong M. Lee - Publications

Vutiglabridin overcomes the GLP-1 RA-associated weight-loss plateau to achieve normal body weight.

Journal: International journal of obesity (2005)

Published: March 13, 2026

Platelet proteomic signatures of amyloid β-positive mild cognitive impairment and Alzheimer's disease.

Journal: Molecular brain

Published: October 13, 2025

Targeting PON2 with Vutiglabridin Restores Mitochondrial Integrity and Attenuates Oxidative Stress-Induced Senescence.

Journal: Antioxidants (Basel, Switzerland)

Published: September 24, 2025

Paraoxonase 2 as a target for aging-related diseases.

Journal: The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology

Published: September 16, 2025

Vutiglabridin ameliorates obesity by directly reducing fat mass through AMPK/lipophagy activation in adipocytes.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: August 31, 2025

Neurotherapeutic effects of Vutiglabridin as a Paraoxonase-2 modulator in preclinical models of Parkinson's disease.

Journal: Molecular neurodegeneration

Published: October 20, 2024

Systematic Proteome Profiling of Maternal Plasma for Development of Preeclampsia Biomarkers.

Journal: Molecular & cellular proteomics : MCP

Published: November 15, 2023

Paraoxonase-2 agonist vutiglabridin promotes autophagy activation and mitochondrial function to alleviate non-alcoholic steatohepatitis.

Journal: British journal of pharmacology

Published: April 06, 2023

Vutiglabridin exerts anti-ageing effects in aged mice through alleviating age-related metabolic dysfunctions.

Journal: Experimental gerontology

Published: March 31, 2023

PRKCSH contributes to TNFSF resistance by extending IGF1R half-life and activation in lung cancer.

Journal: Experimental & molecular medicine

Published: March 08, 2023

Association between Plasma Metabolic Profiles of the Antidepressant Escitalopram and Clinical Response in Subjects with Depression.

Journal: Mass spectrometry (Tokyo, Japan)

Published: February 28, 2023

Synthetic Glabridin Derivatives Inhibit LPS-Induced Inflammation via MAPKs and NF-κB Pathways in RAW264.7 Macrophages.

Journal: Molecules (Basel, Switzerland)

Published: January 20, 2023